[The role of external beam radiation therapy in the adjuvant treatment of pigmented villonodular synovitis]
- PMID: 21271510
- DOI: 10.1055/s-0030-1250687
[The role of external beam radiation therapy in the adjuvant treatment of pigmented villonodular synovitis]
Abstract
Aim: Pigmented villonodular synovitis (PVNS) is a rare proliferative disorder arising from synovial cells of the tendon sheets and joint capsules. The potential value of external beam radiation therapy in the interdisciplinary management of PVNS is demonstrated by a comprehensive literature review on the clinical use of radiotherapy and the results of national patterns of care study (PCS) which was conducted by the German Cooperative Group on Radiotherapy in Benign Diseases (GCG-BD) in 2008-2009.
Material and method: A structured questionnaire was mailed to all 227 RT institutions in Germany to assess all previous treatments, the RT indication and techniques, the rate of local control, the functional outcome and the possible adverse effects related to the use of external beam radiation therapy (RT). For comparison of the clinical outcome data, a systematic literature research in several international electronic databases and a conventional library search were performed to identify publications addressing the use of RT for PVNS.
Results: Based on an overall response rate of 83.2%, the PCS was nationally representative. Ten percent of institutions presented clinical experience with the use of RT for PVNS; from this database a total of 41 treated sites from 14 institutions were evaluable for long-term analysis. The primary therapeutic approach was cytoreductive surgery in all cases. In cases of residual tissue or complete resection of extensive local recurrences, RT was applied in 39 cases (95.1%). An excellent or good functional outcome was noted in 34 cases (82.9%). The use of RT was not associated with early or late toxicity larger than RTOG grade II. The literature review identified 19 published studies (1940-2009) which represented a total of 140 cases or patients, respectively. After follow-up periods ranging from 1-250 months and administration of total doses in the range of 16-50 Gy the overall rate of local control was 84.5%.
Conclusion: Both the results of the national PCS and the literature review demonstrate that RT is a very safe and effective treatment option for the prevention of disease progression or recurrence in PVNS after primary surgical interventions. The planned treatment volume should include the whole synovial space and eventually all invasive components of the disease. Currently, total doses in the range of 30-36 Gy are recommended.
© Georg Thieme Verlag KG Stuttgart · New York.
Similar articles
-
Radiation therapy for treatment of pigmented villonodular synovitis: results of a national patterns of care study.Int J Radiat Oncol Biol Phys. 2010 Sep 1;78(1):199-204. doi: 10.1016/j.ijrobp.2009.07.1747. Epub 2010 May 18. Int J Radiat Oncol Biol Phys. 2010. PMID: 20488628
-
Combined partial arthroscopic synovectomy and radiation therapy for diffuse pigmented villonodular synovitis of the knee.Arthroscopy. 2001 May;17(5):527-31. doi: 10.1053/jars.2001.24068. Arthroscopy. 2001. PMID: 11337722
-
Long-term functional outcomes of diffuse pigmented villonodular synovitis of knee: The role of adjuvant radiotherapy.Medicine (Baltimore). 2021 Mar 26;100(12):e23794. doi: 10.1097/MD.0000000000023794. Medicine (Baltimore). 2021. PMID: 33761628 Free PMC article.
-
Pigmented villonodular synovitis of the temporomandibular joint: case report and the literature review for postoperative radiotherapy.J Radiol Case Rep. 2019 Aug 31;13(8):31-39. doi: 10.3941/jrcr.v13i8.3661. eCollection 2019 Aug. J Radiol Case Rep. 2019. PMID: 31558968 Free PMC article. Review.
-
[Pigmented villonodular synovitis. A rare differential diagnosis of synovial joint swelling].Z Rheumatol. 2016 Mar;75(2):157-65. doi: 10.1007/s00393-015-0028-4. Z Rheumatol. 2016. PMID: 26768272 Review. German.
Cited by
-
Diffuse pigmented villonodular synovitis in knee joint: diagnosis and treatment.Rev Bras Ortop. 2017 Jun 24;52(4):450-457. doi: 10.1016/j.rboe.2017.06.008. eCollection 2017 Jun-Jul. Rev Bras Ortop. 2017. PMID: 28884104 Free PMC article.
-
Diffuse pigmented villonodular synovitis of the knee joint: 3-year follow-up of a case report.Radiat Oncol J. 2022 Dec;40(4):270-275. doi: 10.3857/roj.2022.00122. Epub 2022 Dec 26. Radiat Oncol J. 2022. PMID: 36606304 Free PMC article.
-
Localized Pigmented Villonodular Synovitis in the Shoulder: Report of a Case Treated through Arthroscopy.Rev Bras Ortop (Sao Paulo). 2024 Apr 22;59(Suppl 2):e188-e193. doi: 10.1055/s-0044-1779313. eCollection 2024 Nov. Rev Bras Ortop (Sao Paulo). 2024. PMID: 39735453 Free PMC article.
-
Long-term efficacy of imatinib mesylate in patients with advanced Tenosynovial Giant Cell Tumor.Sci Rep. 2019 Oct 10;9(1):14551. doi: 10.1038/s41598-019-51211-y. Sci Rep. 2019. PMID: 31601938 Free PMC article.
-
Current Systemic Treatment Options for Tenosynovial Giant Cell Tumor/Pigmented Villonodular Synovitis: Targeting the CSF1/CSF1R Axis.Curr Treat Options Oncol. 2016 Feb;17(2):10. doi: 10.1007/s11864-015-0385-x. Curr Treat Options Oncol. 2016. PMID: 26820289 Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources